Valuing Infertility Treatment: Why QALYs Are Inadequate, and an Alternative Approach to Cost-effectiveness Thresholds

Overview

Journal Front Med Technol

Specialty Biomedical Engineering

Date 2023 Jan 9

PMID 36619344

Authors

Elena Keller

Georgina M Chambers

Affiliations

Soon will be listed here.

Citing Articles

Patient-level cost analysis of subfertility pathways in the Dutch healthcare system.

Leusder M, van Elten H, Ahaus K, Hilders C, van Santbrink E Eur J Health Econ. 2024; .

PMID: 39729157 DOI: 10.1007/s10198-024-01744-5.

Economic evaluation of GnRH-agonist long protocol and GnRH-antagonist protocol in IVT/ICSI among the Chinese population: using pharmacoeconomic models.

Si Y, Chen C, Tang Y, Zhang M, Tang J, Pu K BMJ Open. 2024; 14(8):e079715.

PMID: 39153788 PMC: 11331823. DOI: 10.1136/bmjopen-2023-079715.

Impact of Structural Differences on the Modeled Cost-Effectiveness of Noninvasive Prenatal Testing.

Salisbury A, Pearce A, Howard K, Norris S Med Decis Making. 2024; 44(7):811-827.

PMID: 39092556 PMC: 11492563. DOI: 10.1177/0272989X241263368.

Systematic review of the economic evaluation model of assisted reproductive technology.

Si Y, Tan T, Pu K Health Econ Rev. 2024; 14(1):34.

PMID: 38767759 PMC: 11103951. DOI: 10.1186/s13561-024-00509-3.

Applying a simplified economic evaluation approach to evaluate infertility treatments in clinical practice.

Feng Q, Li W, Callander E, Wang R, Mol B Hum Reprod. 2023; 39(3):448-453.

PMID: 38148026 PMC: 10905501. DOI: 10.1093/humrep/dead265.

References

Chambers G, Dyer S, Zegers-Hochschild F, de Mouzon J, Ishihara O, Banker M . International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2014†. Hum Reprod. 2021; 36(11):2921-2934. DOI: 10.1093/humrep/deab198. View

Luo L, Chen M, Wen Y, Zhang L, Zhou C, Wang Q . Pregnancy outcome and cost-effectiveness comparisons of artificial cycle-prepared frozen embryo transfer with or without GnRH agonist pretreatment for polycystic ovary syndrome: a randomised controlled trial. BJOG. 2020; 128(4):667-674. DOI: 10.1111/1471-0528.16461. View

Botha W, Donnolley N, Shanahan M, Norman R, Chambers G . Societal preferences for fertility treatment in Australia: a stated preference discrete choice experiment. J Med Econ. 2018; 22(1):95-107. DOI: 10.1080/13696998.2018.1549055. View

Pashayan N, Lyratzopoulos G, Mathur R . Cost-effectiveness of primary offer of IVF vs. primary offer of IUI followed by IVF (for IUI failures) in couples with unexplained or mild male factor subfertility. BMC Health Serv Res. 2006; 6:80. PMC: 1543624. DOI: 10.1186/1472-6963-6-80. View

Antero M, Singh B, Pradhan A, Gornet M, Kearns W, Baker V . Cost-effectiveness of preimplantation genetic testing for aneuploidy for fresh donor oocyte cycles. F S Rep. 2021; 2(1):36-42. PMC: 8244284. DOI: 10.1016/j.xfre.2020.11.005. View

Lee M, Lofgren K, Thomas A, Lanes A, Goldman R, Ginsburg E . The cost-effectiveness of preimplantation genetic testing for aneuploidy in the United States: an analysis of cost and birth outcomes from 158,665 in vitro fertilization cycles. Am J Obstet Gynecol. 2021; 225(1):55.e1-55.e17. DOI: 10.1016/j.ajog.2021.01.021. View

Hollingsworth B, Harris A, Mortimer D . The cost effectiveness of intracyctoplasmic sperm injection (ICSI). J Assist Reprod Genet. 2007; 24(12):571-7. PMC: 3454996. DOI: 10.1007/s10815-007-9175-0. View

Torrance G, Feeny D, Furlong W, Barr R, Zhang Y, Wang Q . Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care. 1996; 34(7):702-22. DOI: 10.1097/00005650-199607000-00004. View

Shreffler K, Greil A, Tiemeyer S, McQuillan J . Is infertility resolution associated with a change in women's well-being?. Hum Reprod. 2020; 35(3):605-616. PMC: 7105324. DOI: 10.1093/humrep/dez297. View

10.

McIntosh E . Using discrete choice experiments within a cost-benefit analysis framework: some considerations. Pharmacoeconomics. 2006; 24(9):855-68. DOI: 10.2165/00019053-200624090-00004. View

11.

Bordewijk E, Weiss N, Nahuis M, Kwee J, Lambeek A, van Unnik G . Gonadotrophins or clomiphene citrate in women with normogonadotropic anovulation and CC failure: does the endometrium matter?. Hum Reprod. 2020; 35(6):1319-1324. PMC: 7316496. DOI: 10.1093/humrep/deaa052. View

12.

Moolenaar L, Nahuis M, Hompes P, van der Veen F, Mol B . Cost-effectiveness of treatment strategies in women with PCOS who do not conceive after six cycles of clomiphene citrate. Reprod Biomed Online. 2014; 28(5):606-13. DOI: 10.1016/j.rbmo.2014.01.014. View

13.

Basu A, Sullivan S . Toward a Hedonic Value Framework in Health Care. Value Health. 2017; 20(2):261-265. DOI: 10.1016/j.jval.2016.11.022. View

14.

Moolenaar L, Cissen M, de Bruin J, Hompes P, Repping S, van der Veen F . Cost-effectiveness of assisted conception for male subfertility. Reprod Biomed Online. 2015; 30(6):659-66. DOI: 10.1016/j.rbmo.2015.02.006. View

15.

Buhler K, Roeder C, Schwarze J, Lispi M, Allignol A, Falla E . Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry. Best Pract Res Clin Obstet Gynaecol. 2022; 85(Pt B):188-202. DOI: 10.1016/j.bpobgyn.2022.02.002. View

16.

Tough S, Tofflemire K, Benzies K, Fraser-Lee N, Newburn-Cook C . Factors influencing childbearing decisions and knowledge of perinatal risks among Canadian men and women. Matern Child Health J. 2007; 11(2):189-98. DOI: 10.1007/s10995-006-0156-1. View

17.

Shih S, Keller E, Wiley V, Wong M, Farrar M, Chambers G . Economic Evaluation of Newborn Screening for Severe Combined Immunodeficiency. Int J Neonatal Screen. 2022; 8(3). PMC: 9326549. DOI: 10.3390/ijns8030044. View

18.

Suchartwatnachai C, Wongkularb A, Srisombut C, Choktanasiri W, Chinsomboon S, Rojanasakul A . Cost-effectiveness of IVF in women 38 years and older. Int J Gynaecol Obstet. 2000; 69(2):143-8. DOI: 10.1016/s0020-7292(99)00215-5. View

19.

Daya S, Ledger W, Auray J, Duru G, Silverberg K, Wikland M . Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK. Hum Reprod. 2001; 16(12):2563-9. DOI: 10.1093/humrep/16.12.2563. View

20.

Shih S, Keller E, Wiley V, Farrar M, Wong M, Chambers G . Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency. Int J Neonatal Screen. 2022; 8(3). PMC: 9326684. DOI: 10.3390/ijns8030045. View